A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient performance in the first half of 2020 despite COVID-19 headwinds, and the French government’s push for more domestic pharma manufacturing.
Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot (PharmaBoardroom)
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline of BTK inhibitors for autoimmune disorders.
Unither joins the world’s top 5 CDMOs with plants on 4 continents (PharmaNetwork)
Unither Pharmaceuticals, the world leader in sterile unit doses, launches the acquisition of the Chinese pharmaceutical company: Nanjing Ruinian Best Pharmaceutical Co. Ltd. (NRB).
http://www.pharmanetwork.com/magazine/stories/unither-pharmaceuticals.html
Ipsen Presents Its Half Year 2020 Results and Reinstates Guidance for Full Year 2020 (Business Wire)
David Loew, Ipsen CEO: “I am pleased to report that, despite the unprecedented backdrop of COVID-19, Ipsen delivered top-line growth and margin improvement. As a result, we are reinstating guidance for 2020 and planning for the future with confidence.”
Covid-19 hastens French push to bring home medicines manufacture (FT)
President Macron says state is prepared to invest in reshoring, starting with paracetamol
https://www.ft.com/content/80a4836b-ca25-48e0-996d-458186e968dc
